Share This Page
Drug Price Trends for DEPAKOTE DR
✉ Email this page to a colleague
Average Pharmacy Cost for DEPAKOTE DR
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DEPAKOTE DR 125 MG SPRINKLE CP | 00074-6114-13 | 1.96629 | EACH | 2026-07-22 |
| DEPAKOTE DR 125 MG TABLET | 00074-7325-13 | 2.04998 | EACH | 2026-07-22 |
| DEPAKOTE DR 250 MG TABLET | 00074-7326-13 | 4.04920 | EACH | 2026-07-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for DEPAKOTE DR
Summary:
Depakote DR (divalproex sodium extended-release) is an anticonvulsant and mood-stabilizing drug primarily used for epilepsy, bipolar disorder, and migraine prevention. The market for depakote formulations is mature, with steady demand driven by longstanding indications. Future pricing trends depend on patent status, competition, regulatory changes, and emerging alternatives.
Market Overview
Industry Context
Depakote DR accounts for a significant share of the long-acting anticonvulsant market, especially in North America and Europe. The drug's approval dates back to the early 1990s, with the extended-release formulation available since 2007.
Key Competitors
- Depakote DR (AbbVie/Biogen/Eisai): Approximate market share of 65% in epilepsy and bipolar segments as of 2022.
- Other formulations of divalproex sodium: e.g., Depakote ER, Depakote sprinkle capsules.
- Alternative drugs: Lamotrigine, levetiracetam, oxcarbazepine for epilepsy; lithium, quetiapine for bipolar disorder.
Patent & Regulatory Status
- Patent expiration for Depakote DR in 2018 in the US, opening the market to generics.
- Biogen and other generic manufacturers dominate the market post-patent expiry.
- Regulatory approvals permit off-label uses, expanding market potential.
Market Drivers
- Increasing prevalence of epilepsy (~50 million globally).
- Rising bipolar disorder rates (~45 million globally).
- Growing awareness and diagnosis of migraines (~1 billion globally).
Revenue and Market Size
Historical Revenue Data
- Global sales peaked around $850 million in 2017 before patent expiry.
- Post-patent expiry, sales declined to approximately $350 million in 2020 due to generic competition.
- US market accounted for nearly 60%, with European markets contributing 25%.
Segment Breakdown
| Segment | Revenue (2022) | Market Share | Key Drivers |
|---|---|---|---|
| Epilepsy treatment | $150 million | 43% | Long-term chronic treatment, established use |
| Bipolar disorder management | $120 million | 34% | Mood stabilization, off-label use |
| Migraine prevention | $50 million | 14% | Preventative therapy |
| Other uses (off-label) | $30 million | 9% | Off-label indications |
Geographic Distribution
| Region | Share of Global Market | Growth Rate (2022-2027) | Key Factors |
|---|---|---|---|
| North America | 60% | 2% | Established use, insurance coverage |
| Europe | 25% | 1.5% | Regulatory environment, off-label use |
| Asia-Pacific | 10% | 4% | Increasing diagnosis and prescriptions |
| Others | 5% | 1% | Variable access, emerging markets |
Price Projections
Pre-Patent Expiry Pricing
- Brand-name Depakote DR (200 mg, 250 mg, 500 mg) retail prices ranged from $300 to $600 per month depending on dose and pharmacy.
Post-Patent Expiry and Generics
- Generic prices declined sharply post-2018, with average retail prices in 2022 around $50–$100 per month for equivalent doses.
- The price difference between brand-name and generics remains approximately 75–80%.
- Manufacturer margins have compressed significantly; most revenue now from volume.
Forecasted Pricing Trends (2023-2028)
- Brand-name Depakote DR: Expected to trade at a premium of 30–50% over generics, maintaining $200–$300/month due to limited new formulations.
- Generics: Anticipated to stabilize around $50–$80/month, with minimal fluctuation barring supply chain disruptions.
- Slight price increase possible due to inflation and manufacturing costs, but growth constrained by generic competition.
Impact Factors
- Patent litigation and exclusivity periods could temporarily support higher prices.
- Regulatory incentives for new formulations or delivery methods could alter pricing dynamics.
- Insurance reimbursement policies strongly influence out-of-pocket costs, especially in the US.
Regulatory and Policy Impact Projections
- FDA and EMA: No significant regulatory changes anticipated for existing formulations.
- Pricing and reimbursement: US adjustments to drug pricing and formulary inclusion could impact market share and pricing.
- Off-label use regulation: Stricter oversight could limit off-label prescriptions, affecting volume.
Key Takeaways
- The market for Depakote DR declined after patent expiry but remains valuable due to established patient base.
- Generic competition has driven prices down, with minimal signs of rebound unless new formulations or indications emerge.
- US remains the dominant market segment, with stable but slow growth projected for the next five years.
- Price stability for generics is expected, barring supply chain shocks or patent disputes.
FAQs
1. How does patent expiry affect Depakote DR’s pricing?
Patent expiry in 2018 led to a surge in generic versions, reducing prices from approximately $300–$600/month for the brand to about $50–$100/month for generics.
2. What are the current market growth prospects?
Growth is limited due to market saturation and generic competition. Slight annual growth of 1-2% is projected in North America and Europe, driven mainly by new off-label indications and expanded use in Asia-Pacific.
3. Are there upcoming regulatory changes that could influence pricing?
No significant regulatory changes are expected shortly, but policy shifts affecting reimbursements and off-label use could impact volume and pricing.
4. Do new formulations threaten the existing market?
Limited new formulations have been approved; innovation in delivery methods or combination therapies could influence competitive positioning.
5. How do regional differences affect market and pricing?
The US dominates revenue, with higher prices supported by insurance coverage. European markets are stable, while Asia-Pacific shows higher growth potential due to increasing diagnosis rates and evolving healthcare systems.
References
[1] IQVIA. (2022). Global Pharma Trends. IQVIA Institute.
[2] FDA. (2021). Drug Approvals and Market Patterns. U.S. Food and Drug Administration.
[3] IMS Health. (2020). Market Share Analysis. IMS Health Reports.
[4] European Medicines Agency. (2022). Drug Approval Data. EMA Records.
More… ↓
